FMW Stock | | | EUR 0.68 0.00 0.00% |
CEO
Charles Todd is Chief Executive Officer of The Female Health Company Division of VERU INC DL 01 since 2019.
Age | 66 |
Tenure | 5 years |
Phone | 305-509-6897 |
Web | http://www.verupharma.com |
VERU INC Management Efficiency
The company has return on total asset
(ROA) of
(0.331) % which means that it has lost $0.331 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.7187) %, meaning that it generated substantial loss on money invested by shareholders. VERU INC's management efficiency ratios could be used to measure how well VERU INC manages its routine affairs as well as how well it operates its assets and liabilities.
VERU INC DL 01 has accumulated 15.25
M in total debt with debt to equity ratio
(D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. VERU INC DL has a current ratio of 8.1, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist VERU INC until it has trouble settling it off, either with new capital or with free cash flow. So, VERU INC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VERU INC DL sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VERU to invest in growth at high rates of return. When we think about VERU INC's use of debt, we should always consider it together with cash and equity.
Similar Executives
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. VERU INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 3 people. VERU INC DL 01 (FMW) is traded on Frankfurt Exchange in Germany and employs 233 people.
Management Performance
VERU INC DL Leadership Team
Elected by the shareholders, the VERU INC's board of directors comprises two types of representatives: VERU INC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VERU. The board's role is to monitor VERU INC's management team and ensure that shareholders' interests are well served. VERU INC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VERU INC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jesus Socorro, Independent Director | |
| Mario Eisenberger, Independent Director | |
| K Barnette, Chief Scientific Officer | |
| Grace Hyun, Independent Director | |
| Charles Todd, Chief Executive Officer of The Female Health Company Division | |
| Michael Rankowitz, Independent Director | |
| Mitchell Steiner, Chairman of the Board, President, Chief Executive Officer | |
| Michele Greco, Chief Financial Officer, Chief Administrative Officer | |
| Harry Fisch, Vice Chairman of the Board, Chief Corporate Officer | |
VERU Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VERU INC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in VERU Stock
VERU INC financial ratios help investors to determine whether VERU Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in VERU with respect to the benefits of owning VERU INC security.